Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

New Evidence With BTK Inhibitor Therapy in CLL and MCL From EHA 2022

Source: A Global Perspective on Emerging BTK Inhibitor Therapy Data for Relapsed/Refractory CLL and MCL in 2022*
2022 ASCO Annual Meeting, June 3-7, 2022, in Chicago, Illinois, USA; EHA 2022 Congress, June 9-12, 2022, in Vienna, Austria; 2022 Pan Pacific Lymphoma Conference, July 18-22, 2022, in Koloa, Hawaii, USA; ESMO 2022 Annual Congress, September 9-13, 2022, in Paris, France; 2022 SOHO Annual Meeting, September 28 - October 1, 2022, in Houston, Texas, USA
Gain insight into expert faculty perspectives as they discuss recent key studies from EHA 2022 on BTK inhibition in chronic lymphocytic leukemia and mantle cell lymphoma and their potential implications for clinical practice.
Othman Al-Sawaf, MD
Lydia Scarfò, MD
Released: July 21, 2022

In this episode, Othman Al-Sawaf, MD, and Lydia Scarfò, MD, discuss key trials presented at EHA 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of:

  • GAIA/CLL13: phase III trial of time-limited venetoclax + obinutuzumab ± ibrutinib vs chemoimmunotherapy as first-line therapy for CLL
  • FLAIR: randomized, adaptive-design phase III trial with data reported from ibrutinib + venetoclax and ibrutinib arm; includes measurable residual disease–defined therapy duration
  • BRUIN: phase I/II study of pirtobrutinib for previously treated CLL (including previous BTK inhibitor)
  • SHINE: phase III study of ibrutinib with bendamustine + rituximab and rituximab maintenance in older patients with MCL

Information on this Educational Activity

Faculty

Othman Al-Sawaf, MD

Medical Doctor
Dep I of Internal Medicine
University Hospital of Cologne
Cologne, Germany

Othman Al-Sawaf, MD: honoraria: AbbVie, Adaptive Biotechnologies, Ascentage, AstraZeneca, BeiGene, Gilead Sciences, Janssen-Cilag, Roche; consultant/advisor: AbbVie, Gilead Sciences, Janssen-Cilag, Roche; researcher (institution): AbbVie, BeiGene, Janssen/Pharmacyclics, Roche; travel/accommodations/expenses: AbbVie, Gilead Sciences, Janssen-Cilag, Roche.
Lydia Scarfò, MD

Assistant Professor
Internal Medicine
Università Vita-Salute San Raffaele
Consultant Hematologist
Strategic Research Program on CLL
Milan, Italy

Lydia Scarfò, MD: honoraria: AbbVie, AstraZeneca, BeiGene, Janssen, Octapharma; travel grants: BeiGene, Janssen.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC.
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Lilly

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings